Jump to Navigation

Antipsychotics > Research Update

Off-Label Use of Antipsychotics Effective for Some Indications

Over the past decade or so, atypical antipsychotic use has exploded, for both FDA approved indications and off-label treatments. A recent meta-analysis examined the efficacy (when compared to placebo), comparative effectiveness (when compared to another medication), and safety of atypicals.

Switching Antipsychotics Reduces Cardiovascular Risk Factors

If patients are stable on olanzapine (Zyprexa), quetiapine (Seroquel), or risperidone (Risperdal) but are experiencing adverse metabolic effects, it might make sense to switch to a medication that has a lower risk of causing such effects. But would such a switch reduce obesity and cholesterol at the risk of a relapse?

Is One Antipsychotic Just as Effective as Two?

Using combination antipsychotic treatment has become more common over the years, presumably reflecting a common sense theory that in refractory patients, two medications might be more effective than one. But studies thus far of the practice have been small and inconclusive.

Antipsychotics May Shrink Brains of Schizophrenics

A study has been published that appears to show that antipsychotic treatment actually shrinks the brain.

Are Depot Antipsychotics More Effective than Oral Meds? Maybe

Clinical folklore (and occasional drug reps) have suggested that depot antipsychotics have adherence advantages over their oral counterparts.

Atypicals No Better Than Typicals in Depression with Schizophrenia

Second generation antipsychotics have developed a reputation for being more effective for treating a number of the symptoms of schizophrenia than their first generation counterparts, even if research doesn’t always back up this claim.